Paediatric Early Rehabilitation/Mobilisation During InTensive Care (PERMIT)

Paediatric Early Rehabilitation/Mobilisation During InTensive Care: An Observational Study

In the UK, critical illness or injury affects about 19,000 Children and Young Persons (CYP) every year who are admitted to the paediatric intensive care unit (PICU) to receive life-sustaining treatments. Although survival rates from PICU are at an all-time high (>96%), low levels of mortality have been offset by an increase in morbidity. The impact of being critically ill and exposed to the PICU is multiple. Weakness, cognitive impairment, organ dysfunction, and psychological problems have been reported to emanate from deconditioning. Subsequently, post-PICU many CYP experience significant and residual physical, cognitive, and psychosocial morbidities that impact on their quality of life. The contemporary focus has turned to the development, testing, and implementation of interventions to minimize the harmful effects of critical care and maximize patient outcomes.

Early rehabilitation and/or mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package, provided by health professionals from multiple disciplines and care-givers within intensive care settings to promote recovery, both physical (e.g. movement, functional activities, ambulation) and non-physical (e.g. speech, play, psychological, cognitive).

Rehabilitation has been shown to improve quality of life and patient outcomes; reduce health inequalities, and make significant savings to the health care system. Benefits have been demonstrated in the use of ERM in adult ICU populations in relation to patient outcomes as well as healthcare utilization. Studies also indicate that the intervention is safe and feasible, reduces delirium and increases ventilator-free days, improves day-to-day functioning and reduces hospital readmissions. However, in the United Kingdom (UK), the understanding of current ERM practices (including content, barriers, facilitators, feasibility, and safety) and their impact on the outcomes of pediatric ICU patients is limited. This has stifled an evidence-based approach to ERM which has resulted in disparity in the adoption and utilization of ERM interventions in PICUs across the UK.

To address this critical gap, the first phase of a four-phase program of the PERMIT study will generate evidence of current PICU ERM practices by conducting a survey and an observational study.

The second phase of the study will involve conducting qualitative workshops to develop a prototype ERM program. Qualitative workshops will also be conducted among key stakeholders (clinicians, parents, CYP) to inform the design of an ERM intervention.

The third phase will investigate this ERM program in a pilot study in UK PICUs and finally, the efficacy of the intervention will be tested using a large scale, definitive randomized controlled trial (RCT).

Study Overview

• Status: Unknown
• Conditions: Critical Illness; ICU

Detailed Description

The PERMIT study aims to ascertain current ERM practices within PICU settings and barriers/facilitators to ERM delivery.

The investigators plan to directly observe current ERM practices within UK PICUs, identify patients who do and do not receive ERM, describe the variation between PICUs and factors associated with ERM practices.

Inclusion Criteria:

1. All Children and Young Persons (CYP) (0-<16 years)
2. Admitted to PICU
3. Remain within PICU on day 3 post-admission

The broad inclusion criteria will allow for the observation of all types of patients admitted for PICU care (acute and elective e.g. post-surgical recovery) and all age ranges.

Exclusion criteria:

1. A local decision by a Principal investigator (PI) or treating clinical team not to include patient
2. Parent or guardian chooses to opt-out

Prospective data about all children admitted to PICU for 3 days or more will be collected. Eligible patients will be identified, screened and enrolled in the study. Posters and patient information leaflets will be provided to parents/legal guardians within participating PICU explaining their rights to withdraw from the study without affecting the future care of their child. Data collected as part of the study will be stored for ten years, in line with Good Clinical Practice (GCP) guidelines. No identifiable data will be collected or shared with the PERMIT study team at any time.

Following the observation of current ERM delivery and identification of patients who may benefit from ERM in selected PICUs, the study investigators will use this information to model how many patients may be available in the UK for a potential future RCT. This will be achieved by modeling patient demographic information with the Paediatric Intensive Care Audit Network (PICANet) dataset.

• Study Type: Observational
• Enrollment (Anticipated): 150

Contacts and Locations

• Study Contact: Name: Barnaby Scholefield, Dr; Phone Number: 07968722758; Email: b.scholefield@bham.ac.uk
• Study Contact Backup: Name: Jacqueline Thompson, MPH; Phone Number: 012141459107; Email: j.y.thompson@bham.ac.uk

Study Locations

• United Kingdom
  • West Midlands
    • Birmingham, West Midlands, United Kingdom, B4 6NH
      • Birmingham Women's and Children's Hospital PICU
      • Contact: Barnaby Scholefield, Dr; Phone Number: 7968722758; Email: iia-permitstudy@contacts.bham.ac.uk
      • Contact: Jacqueline Thompson; Phone Number: 012141459107; Email: j.y.thompson@bham.ac.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 months to 16 years (Child)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All Children and Young Persons (CYP) (0-<16 years) admitted to paediatric itnesive care units for 3 days or more

Description

Inclusion Criteria:

• All Children and Young Persons (CYP) (0-<16 years)
• Admitted to PICU
• Remain within PICU on day 3 post-admission

Exclusion Criteria:

• Local decision by PI or treating clinical team not to include patient
• Parent or guardian choose to opt out.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of early rehabilitation and/or mobilisation (ERM) delivered on Day 3 post PICU admission	The prevalence and scope of ERM will be described as the proportion of patients with any 'active interaction' delivered on Day 3 post-admission.	3 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence rates and ratios of the number of ERM interventions from Day 3 to Day 10 post PICU admission	Incidence rates will be calculated and exploratory analysis will be performed to understand factors associated with the incidence of ERM delivery.	3 weeks
The cumulative prevalence of ERM for each day in PICU after Day 3 up to Day 10 post-admission	The cumulative prevalence for each day in PICU after Day 3 up to Day 10 post-admission with whom ERM may/may not be appropriate will be calculated. Exploratory analysis will be performed to understand factors associated with the incidence of ERM delivery.	3 weeks
Factors associated with variability of early rehabilitation and/or mobilisation (ERM) delivery	Exploratory analysis will be performed to understand factors associated with ERM delivery. ERM delivered per patient will be quantified as well as the characteristics of patients receiving ERM, type of ERM interventions delivered and factors associated with variability of delivery between PICUs will be explored.	3 weeks
To evaluate predictors of ERM provided on Day 3 post-PICU-admission	Exploratory analysis will be used to explore the characteristics of patients receiving ERM on Day 3 post-PICU-admission. Multilevel multivariable regression models will be used to evaluate predictors of ERM provision	3 weeks
Dose of ERM per day of PICU admission	Exploratory analysis will be performed to quantify the dose (duration, measured in minutes) of ERM for each day over the 3-week period of the study.	3 weeks

Collaborators and Investigators

• Sponsor: University of Birmingham
• Collaborators: University of Nottingham; Imperial College London; University of Leeds; Newcastle University; University of Cambridge; Northumbria University
• Investigators: Study Chair: Barnaby Scholefield, Dr, Birmingham Women's and Children's Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): October 28, 2019
• Primary Completion (Anticipated): November 30, 2019
• Study Completion (Anticipated): October 31, 2020

Study Registration Dates

• First Submitted: August 14, 2019
• First Submitted That Met QC Criteria: September 30, 2019
• First Posted (Actual): October 1, 2019

Study Record Updates

• Last Update Posted (Actual): October 1, 2019
• Last Update Submitted That Met QC Criteria: September 30, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Keywords: Observational; Early rehabilitation; Paediatric; Early mobilisation; PICU
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Critical Illness
• Other Study ID Numbers: RG_18-161

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No